1. Simultaneous determination of Rivaroxaban and TAK-438 in rat plasma by LC–MS/MS: application to pharmacokinetic interaction study
- Author
-
Nan Zhou, Libin Wang, Nan Gou, Xiaohui Xu, Shouchang Gai, Xiaorui Zhang, Tian Feng, and Xingchen Wang
- Subjects
Male ,Quality Control ,Clinical Biochemistry ,030204 cardiovascular system & hematology ,01 natural sciences ,Analytical Chemistry ,Rats, Sprague-Dawley ,03 medical and health sciences ,0302 clinical medicine ,Rivaroxaban ,Tandem Mass Spectrometry ,Lc ms ms ,medicine ,Animals ,Drug Interactions ,Pyrroles ,General Pharmacology, Toxicology and Pharmaceutics ,Chromatography, High Pressure Liquid ,Sulfonamides ,Chromatography ,Chemistry ,010401 analytical chemistry ,Reproducibility of Results ,General Medicine ,Carbamazepine ,Rats ,0104 chemical sciences ,Medical Laboratory Technology ,Pharmacokinetic interaction ,Half-Life ,medicine.drug - Abstract
Aim: A sensitive and reliable LC–MS/MS method has been established and validated to the quantitation of rivaroxaban (RIV) and TAK-438 in rat plasma using carbamazepine as internal standard. Results: The procedure of method validation was conducted according to the guidelines of EMA and US FDA. At the same time, the method was applied to pharmacokinetic interactions study between RIV and TAK-438 for the first time. When RIV and TAK-438 co-administration to rats, main pharmacokinetic parameters of TAK-438 like AUC(0-t), AUC(0-∞) and Cmax had statistically significant increase. The main pharmacokinetic parameters of RIV have no statistically significant difference (p > 0.05) when co-administered except for t1/2 (p < 0.01). Conclusion: The results indicated that drug–drug interactions occurred between RIV and TAK-438 when co-administered to rats.
- Published
- 2020
- Full Text
- View/download PDF